Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Beats Estimates By $0.07 EPS

07 May 2026, 22:16 by Doug Wharley · The Cerbat Gem

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07, FiscalAI reports. The firm had revenue of $1.19 million for the quarter, compared to the consensus estimate of $8.79 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.

Voyager Therapeutics Stock Down 5.0%

NASDAQ VYGR traded down $0.21 during trading hours on Thursday, hitting $3.96. 459,926 shares of the company were exchanged, compared to its average volume of 498,707. The stock has a 50-day moving average price of $4.04 and a 200 day moving average price of $4.06. Voyager Therapeutics has a 52 week low of $2.64 and a 52 week high of $5.55. The stock has a market cap of $239.26 million, a PE ratio of -1.95 and a beta of 1.26.

Insider Activity

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of the company’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the completion of the sale, the chief executive officer owned 484,060 shares in the company, valued at $1,834,587.40. This represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 61,294 shares of company stock worth $233,241 in the last ninety days. 6.39% of the stock is owned by insiders.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Opaleye Management Inc. purchased a new position in shares of Voyager Therapeutics during the 4th quarter worth approximately $4,704,000. AQR Capital Management LLC boosted its position in Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after buying an additional 317,927 shares during the period. Acadian Asset Management LLC boosted its position in Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after buying an additional 206,758 shares during the period. Two Sigma Investments LP purchased a new position in Voyager Therapeutics in the 3rd quarter valued at approximately $657,000. Finally, Sphera Funds Management LTD. boosted its position in Voyager Therapeutics by 70.1% in the 4th quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company’s stock valued at $1,335,000 after buying an additional 140,000 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on VYGR shares. Truist Financial upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Wednesday, April 15th. Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $16.50.

View Our Latest Analysis on Voyager Therapeutics

About Voyager Therapeutics

(Get Free Report)

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.